Search

UCB SA

Fechado

SetorSaúde

170.3 -1.28

Visão Geral

Variação de preço das ações

24h

Atual

Mín

170.05

Máximo

174.4

Indicadores-chave

By Trading Economics

Rendimento

857M

Vendas

3.4B

P/E

Médio do Setor

31.06

39.564

Rendimento de Dividendos

0.83

Margem de lucro

25.498

Funcionários

9,052

EBITDA

1.3B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+19.23% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.83%

2.40%

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3.4B

32B

Abertura anterior

171.58

Fecho anterior

170.3

Sentimento de Notícias

By Acuity

50%

50%

148 / 376 Ranking em Healthcare

UCB SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de jul. de 2025, 22:07 UTC

Grandes Movimentos do Mercado

Trade Desk Rises on S&P 500 Inclusion

14 de jul. de 2025, 17:06 UTC

Grandes Movimentos do Mercado

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 de jul. de 2025, 16:47 UTC

Aquisições, Fusões, Aquisições de Empresas

NatWest to Sell Stake in Permanent TSB

14 de jul. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

14 de jul. de 2025, 23:38 UTC

Conversa de Mercado

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 de jul. de 2025, 23:37 UTC

Conversa de Mercado

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 de jul. de 2025, 23:29 UTC

Conversa de Mercado

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 de jul. de 2025, 23:29 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

14 de jul. de 2025, 23:02 UTC

Ganhos

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 de jul. de 2025, 23:02 UTC

Ganhos

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 de jul. de 2025, 23:02 UTC

Ganhos

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 de jul. de 2025, 23:01 UTC

Ganhos

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 de jul. de 2025, 23:01 UTC

Ganhos

China Vanke Expects 1H Loss to Widen >000002.SZ

14 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

14 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

14 de jul. de 2025, 20:07 UTC

Conversa de Mercado

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 de jul. de 2025, 20:05 UTC

Conversa de Mercado

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 de jul. de 2025, 19:11 UTC

Conversa de Mercado

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 de jul. de 2025, 19:09 UTC

Conversa de Mercado

Gold Breaks a 3-Day Win Streak -- Market Talk

14 de jul. de 2025, 18:59 UTC

Conversa de Mercado

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 de jul. de 2025, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 de jul. de 2025, 18:25 UTC

Conversa de Mercado

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 de jul. de 2025, 18:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de jul. de 2025, 16:59 UTC

Conversa de Mercado

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 de jul. de 2025, 16:53 UTC

Ações em Alta

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 de jul. de 2025, 16:27 UTC

Conversa de Mercado

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

14 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

14 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

14 de jul. de 2025, 16:12 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

UCB SA Previsão

Preço-alvo

By TipRanks

19.23% parte superior

Previsão para 12 meses

Média 94.86 EUR  19.23%

Máximo 125 EUR

Mínimo 74 EUR

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para UCB SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

7 ratings

4

Comprar

1

Manter

2

Vender

Sentimento

By Acuity

148 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.